Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C powder. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
0 transactions — 0 buys and 0 sales reported by Staidson (Beijing) BioPharmaceuticals Co., Ltd. executives.
0 institutional funds report a position on 300204.SZ in their latest SEC quarterly filing.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of 300204.SZ on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year